Novo Nordisk has had a tough time over the past 13 months, with its stock falling significantly. The main reason is growing investor concern that the explosive growth in sales of Wegovy and Ozempic may be slowing down, especially as competition heats up — particularly from Eli Lilly. Just a few days ago, Novo cut its full-year growth forecast, which confirmed some of those market worries.
At the same time, they announced a leadership change. Current CEO Lars Fruergaard Jørgensen is stepping down, and from August 7, Mike Doustdar will take over. He’s been with Novo since 1992 and has led the company’s international operations with great success. He’s also completed executive education at Harvard, and he’s widely seen as a strong, action-oriented leader with global experience.
Looking at the chart the price has almost always swayed up and down within this tunnel. Occationally falling to the trendline bellow.
Now we are at the trendline below - Meaning we are at an absolute panic state. One og the biggest pharma companies in the world - who in a matter of 5 years will bring a weight loss pill to this world - is ready for a new start.
Still somewhat of a falling knife - so be careful. But keep an eye out for a speedy return upwards.
LLY on the other hand has a bit of the same trend BUT… price has hit the top of the channel…
At the same time, they announced a leadership change. Current CEO Lars Fruergaard Jørgensen is stepping down, and from August 7, Mike Doustdar will take over. He’s been with Novo since 1992 and has led the company’s international operations with great success. He’s also completed executive education at Harvard, and he’s widely seen as a strong, action-oriented leader with global experience.
Looking at the chart the price has almost always swayed up and down within this tunnel. Occationally falling to the trendline bellow.
Now we are at the trendline below - Meaning we are at an absolute panic state. One og the biggest pharma companies in the world - who in a matter of 5 years will bring a weight loss pill to this world - is ready for a new start.
Still somewhat of a falling knife - so be careful. But keep an eye out for a speedy return upwards.
LLY on the other hand has a bit of the same trend BUT… price has hit the top of the channel…
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.